Drug Safety Research Unit (DSRU)
James Bell is a professional with extensive experience in safety, vigilance, and medical affairs quality assurance. James has held various roles at AbbVie, University of Portsmouth, and Drug Safety Research Unit. At AbbVie, James has served as a Director, Associate Director, and Senior Manager in quality assurance and compliance roles. James has also worked as a Partner Associate Lecturer at the University of Portsmouth and as an Educational Course Leader and Guest Educational Speaker at Drug Safety Research Unit. Prior to this, James held positions at RB as a Vigilance Quality Manager, Global Vigilance Compliance Lead, Senior Safety Associate, and Vigilance Compliance Officer. James holds a Post-graduate Diploma in Pharmacovigilance from the University of Portsmouth.
Drug Safety Research Unit (DSRU)
At the Drug Safety Research Unit (DSRU), our aim is to achieve the highest possible scientific and ethical standards, by putting the interests of patients first and to work with integrity and fairness with all our partners. Through our historical links with doctors in the NHS, the unit conducts studies in both primary and secondary care, many of which are risk management studies which are part of Risk Management Plans (RMPs) in the EU. Our activities are principally concerned with pharmacovigilance, that is, the detection of side-effects associated with the use of marketed drugs. The DSRU undertakes all forms of research studies and evaluations of the safety of medicines. We are an independent unit providing scientific excellence demonstrated through conducting studies, which have been used to support public health decisions and production of publications in international peer reviewed journals since 1980. The DSRU makes significant, valuable contributions in the area of post marketing surveillance of pharmaceutical products. We have achieved both recognition and endorsement by regulatory authorities, healthcare professionals and the pharmaceutical industry worldwide.